Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.

View the SPC...

Download the Spectrilla SPC. You will need Adobe Reader to view this document.

Get "spc-spectrila-01_2016.pdf"...


Medicines Information Request

Click here to fill in a medicines information form about this product